Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Cabotegravir Sodium

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1051375-13-3, Gsk1265744b, Gsk-1265744b, Vocabria, S-265744b, Cabotegravir sodium [usan]
    Molecular Formula
    C19H16F2N3NaO5
    Molecular Weight
    427.3  g/mol
    InChI Key
    AEZBWGMXBKPGFP-KIUAEZIZSA-M
    FDA UNII
    3L12PT535M
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    sodium;(3R,6S)-12-[(2,4-difluorophenyl)methylcarbamoyl]-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-dien-10-olate
    2.1.2 InChI
    InChI=1S/C19H17F2N3O5.Na/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21;/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27);/q;+1/p-1/t9-,14+;/m0./s1
    2.1.3 InChI Key
    AEZBWGMXBKPGFP-KIUAEZIZSA-M
    2.1.4 Canonical SMILES
    CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)[O-].[Na+]
    2.1.5 Isomeric SMILES
    C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)[O-].[Na+]
    2.2 Other Identifiers
    2.2.1 UNII
    3L12PT535M
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

    2. Apretude

    3. Cabotegravir

    4. Cabotegravir Extended-release Injectable Suspension

    5. Gsk-1265744

    6. Gsk-1265744a

    7. Gsk-1265744b

    8. Gsk1265744

    9. Gsk1265744a

    10. Gsk1265744b

    11. Gsk744

    12. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

    13. S-265744

    14. S-265744b

    15. Sodium (3s,11ar)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate

    16. Vocabria

    2.3.2 Depositor-Supplied Synonyms

    1. 1051375-13-3

    2. Gsk1265744b

    3. Gsk-1265744b

    4. Vocabria

    5. S-265744b

    6. Cabotegravir Sodium [usan]

    7. Cabotegravir (sodium)

    8. S 265744b

    9. 3l12pt535m

    10. Sodium (3s,11ar)-8-((2,4-difluorobenzyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate

    11. Oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide, N-((2,4-difluorophenyl)methyl)-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, Sodium Salt (1:1), (3s,11ar)-

    12. Sodium (3s,11ar)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate

    13. Unii-3l12pt535m

    14. Chembl3137330

    15. Cabotegravir Sodium (jan/usan)

    16. Cabotegravir Sodium [jan]

    17. Chebi:172948

    18. Amy30044

    19. Cabotegravir Sodium [who-dd]

    20. Gsk 1265744b

    21. Hy-15592a

    22. Cabotegravir Sodium [orange Book]

    23. Ac-30853

    24. Cs-0007799

    25. D10549

    26. F11513

    27. A935003

    28. Q27257476

    29. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, Sodium Salt

    30. 1229006-16-9

    31. Sodium (3s,11ar)-8-[(2,4-difluorobenzyl)carbamoyl]-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate

    32. Sodium(3s,11ar)-8-((2,4-difluorobenzyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazin-6-olate

    2.4 Create Date
    2010-07-06
    3 Chemical and Physical Properties
    Molecular Weight 427.3 g/mol
    Molecular Formula C19H16F2N3NaO5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count3
    Exact Mass427.09557123 g/mol
    Monoisotopic Mass427.09557123 g/mol
    Topological Polar Surface Area102 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity820
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

    - oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.

    - oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.

    Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    HIV Integrase Inhibitors

    Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. (See all compounds classified as HIV Integrase Inhibitors.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]; Organic Anion Transporter 1 Inhibitors [MoA]; Organic Anion Transporter 3 Inhibitors [MoA]; HIV Integrase Inhibitors [MoA]
    5.3 ATC Code

    J05AX